(A61K39/395)

Fusion serpine polypeptides and methods for their application // 2642310
FIELD: biotechnology.SUBSTANCE: invention relates to the field of fusion proteins for serine proteases inhibition, and can be used in medicine. Fusion proteins having at least one human alpha-1 antitrypsin (AAT) polypeptide operably linked to an immunoglobulin Fc polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:6 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.18 cl, 4 dwg, 4 ex

Cancer treatment using targeted antibodies in vivo // 2642305
FIELD: biotechnology.SUBSTANCE: antibody binding to claudine 6 (CLDN6) and inhibiting tumor growth in vivo is claimed. The antibody can be used as part of a pharmaceutical composition, in a method for treatment of tumor related to cells expressing CLDN6. The invention also relates to hybridomas producing antibodies to CLDN6 deposited under the accession numbers DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), DSM ACC3057 (GT512muMAB 5F2D2).EFFECT: invention effectively inhibits the growth of CLDN6-positive germ cell tumors, improves survival and prolongs life of patients with tumors.17 cl, 18 dwg, 5 ex

Thrombin-binding molecules of antibodies and their application // 2642276
FIELD: pharmacology.SUBSTANCE: isolated antibody molecule, specifically binding to the thrombin exosite area 1, and an antigen-binding fragment of said antibody, are provided. The use of the antibody molecule in the manufacture of medicaments is considered. A pharmaceutical composition is described as well as a method for treating a thrombin-mediated condition.EFFECT: use in the treatment of diseases associated with thrombin.25 cl, 22 dwg, 4 tbl

Humanized antibodies, which recognize alpha-sinuclein // 2642262
FIELD: biotechnology.SUBSTANCE: antibody is described comprising a mature variable region of the heavy chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 44 and at least 90% identical to the sequence of SEQ ID NO: 44 and a light chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 45, and at least 90% identical to the sequence of SEQ ID NO: 45, where the antibody specifically binds to a human alpha-synuclein. A pharmaceutical composition comprising the described antibody is also described. A method of treating a patient having a disease with Levy bodies or having a risk of developing the disease or a method for detecting Levy bodies in a patient having a disease with Levy bodies or having a risk of developing the disease, comprising appointing to the patient an effective regimen for administering the described antibody, is provided.EFFECT: invention provides antibodies which bind to a human alpha-synuclein and can be used to treat and diagnose a disease with Levy bodies.80 cl, 6 dwg, 5 tbl, 2 ex

Pharmaceutical composition for cancer treatment and prevention // 2641260
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody or a binding fragment thereof that specifically binds to the CAPRIN-1 protein and has immunological reactivity to the partial CAPRIN-1 polypeptide. Also a conjugate, as well as a pharmaceutical composition and a pharmaceutical combination for treatment or prevention of a malignant tumour expressing CAPRIN-1 are disclosed. The invention also relates to a method for treatment or prevention of a cancer expressing CAPRIN-1 using the above antibody or a fragment thereof, a conjugate, a composition or a combination.EFFECT: invention enables efficient treatment or prevention of cancer expressing CAPRIN-1.19 cl, 12 ex

Heterodimerizated polypeptide // 2641256
FIELD: biotechnology.SUBSTANCE: polypeptide with cytotoxic activity, comprising an Fc region of IgG, which consists of a heterodimer containing the first polypeptide and the second polypeptide, in the amino acid sequences of which a series of mutations takes place. A pharmaceutical composition for treatment of a human disease associated with antigens with which the said polypeptide specifically interacts, comprising the said polypeptide and a medically acceptable carrier, is provided.EFFECT: group of inventions allows to optimize the effector function of the polypeptide by changing the function of the Fc region compared to the function of the Fc region of the polypeptide, which consists of a homodimer containing only the first or only the second polypeptide.7 cl, 54 dwg, 80 tbl, 29 ex

at40 antibody binding with domain i of extracellular part of epidermal her2/cd340 growth factor receptor, and its application for cancer treatment // 2640259
FIELD: biotechnology.SUBSTANCE: antibody that binds to the epidermal HER2/CD340 growth factor receptor is disclosed. Application of this antibody to treat cancer with HER2 overexpression is also considered. The antibody of the present invention binds to domain I of the extracellular portion of HER2.EFFECT: high efficiency of cancer treatment.3 cl, 4 dwg, 2 tbl, 8 ex

Antibodies against nerve growth factor and methods for their production and application // 2640254
FIELD: biotechnology.SUBSTANCE: invention relates to a method for production of antibodies suitable for use in cats that are specifically associated with the cat nerve growth factor (NGF) and neutralise the ability of the cat NGF to contact the cat NGF p75 or TrkA receptor and the corresponding antibodies. To implement this method, a donor antibody is obtained from a species other than a cat, the donor antibody having a binding specificity for the target antigen present in cats. Then, each amino acid residue in the sequence of the framework regions of the donor antibody is compared to each amino acid residue present at the corresponding position in the sequence of the framework regions of cat antibodies pool. Then, the identified amino acid residues in the donor antibody are replaced with the amino acid residues present at the corresponding position in the pool of cat antibodies. The resulting antibody does not contain any amino acid foreign at the corresponding position in cats, at any position within the framework regions. This invention also discloses a pharmaceutical composition and a kit containing the said antibodies for treatment of pain in cats, in particular pain associated with arthritis or osteoarthritis immune-mediated rheumatoid arthritis.EFFECT: decrease or loss of antigen-binding activity is avoided.16 cl, 17 dwg, 16 tbl, 11 ex

Bispecific anti-vegf/anti-ang-2 antibodies // 2640253
FIELD: biotechnology.SUBSTANCE: invention relates to a bispecific antibody specifically binding to a human vascular endothelial growth factor-VEGF and human angiopoietin-2-ANG-2, a pharmaceutical composition containing it, as well as a method for its preparation. Also a nucleic acid encoding the above antibody and a vector or host cell containing the aforementioned nucleic acid are disclosed.EFFECT: invention allows effective treatment of cancer and/or vascular diseases.12 cl, 19 dwg, 18 tbl, 20 ex

Antibodies against nerve growth factor and methods for their production and application // 2640252
FIELD: biotechnology.SUBSTANCE: invention relates to a method for production of antibodies suitable for use in horses that are specifically associated with the horse nerve growth factor (NGF) and neutralise the ability of the horse NGF to contact the horse NGF p75 or TrkA receptor and the corresponding antibodies. To implement this method, a donor antibody is obtained from a species other than a horse, the donor antibody having a binding specificity for the target antigen present in horses. Then, each amino acid residue in the sequence of the framework regions of the donor antibody is compared to each amino acid residue present at the corresponding position in the sequence of the framework regions of horse antibodies pool. Then, the identified amino acid residues in the donor antibody are replaced with the amino acid residues present at the corresponding position in the pool of horse antibodies. The resulting antibody does not contain any amino acid foreign at the corresponding position in horses, at any position within the framework regions. This invention also discloses a pharmaceutical composition and a kit containing the said antibodies for the treatment of pain or an NGF-induced tumour in horses.EFFECT: decrease or loss of antigen-binding activity is avoided.12 cl, 11 dwg, 8 tbl, 10 ex

ethods, compositions and instruments for facilitation of regeneration // 2640249
FIELD: biotechnology.SUBSTANCE: methods for of promotion of tissue or organ regeneration in a patient by destroying partially functioning or not functioning cells or ageing cells containing glycation end-product, and for overcoming of effects of aging and a method for to selective destruction of ageing cells in a patient. The proposed methods involve administration of sn antibody that binds to the said final cell glycation product. The presented group of inventions is applicable in medicine.EFFECT: improved regeneration.20 cl, 1 dwg, 3 ex

Pharmaceutical composition for liver cancer treatment and/or prevention // 2640245
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment and/or prevention of liver cancer with surface expression of a CAPRIN-1 protein, that contains an anti-CAPRIN-1 protein is provided. In addition, a pharmaceutical kit and a method for treatment and/or prevention of liver cancer expressing the CAPRIN-1 protein are observed.EFFECT: invention can find further application in liver cancer therapy.9 cl, 16 ex

Cd89 activation in therapy // 2640082
FIELD: pharmacology.SUBSTANCE: for CD89 activation neutrophil therapy, inflammations previously activated by a stimulus, are brought into contact with an effective dose of molecules that activate CD89 and contain Fc-alpha.EFFECT: CD89 activation increases apoptosis in neutrophils, which provides inhibition of inflammation in autoimmune and inflammatory diseases.18 cl, 13 dwg, 8 ex

ethods and compositions for asthma treatment using antibodies against il-13 // 2640025
FIELD: pharmacology.SUBSTANCE: method includes intravenous administration to an individual an antibody against IL-13 or its antigen-binding portion in a dose of about 0.3 mg/kg. Antibody against IL-13 or its antigen-binding portion contain a variable region of heavy chain SEQ ID NO:2 and variable region of light chain SEQ ID NO:3, where at least one pharmacokinetic characteristic, isolated from the group consisting of: (a) the maximum serum concentration (Smax), equal to about 55 to about 90 μg/ml, and (b) the area under the concentration-time curve for serum (AUC) which is equal to approximately 20000 up to approximately 34000 mcg/ml, is reached after administration of antibody or its antigen-binding part to a specified individual. The group of inventions also refers to variants of a method of treating bronchial asthma from mild to moderate form.EFFECT: optimum dosage and the schedule for administration of the above antibody to produce certain pharmacokinetic characteristics.9 cl, 4 ex, 7 tbl, 12 dwg

ethod for gm-csfrα inhibition in patient // 2639546
FIELD: medicine.SUBSTANCE: method for inhibition or neutralisation of the alpha chain activity of the colony-stimulating granulocyte/macrophage (GM-CSFRα) factor in a patient, comprising administration of a composition containing an effective amount of an antibody to human GM-CSFRα. In addition, methods for treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease or myeloid leukaemia in a patient are contemplated. This invention may find use in the therapy of other diseases associated with GM-CSFRα.EFFECT: increased efficiency of treatment.12 cl, 9 dwg, 5 tbl

Antibodies and immunoconjugates and their applications // 2639543
FIELD: biotechnology.SUBSTANCE: humanized antibody specific for STEAP-1 and its antigen-binding fragment are proposed. A polynucleotide encoding an antibody or an antigen-binding fragment thereof, a vector, a host cell, a method for anti-STEAP-1 antibody production are described. A method for tumour visualization, a pharmaceutical composition, a medicament for cell proliferative disorder treatment, immunoconjugates and a cysteine-based antibody based on the said antibody are also disclosed.EFFECT: invention provides new antibodies to STEAP-1 and can be used in medicine.30 cl, 29 dwg, 2 tbl, 9 ex

ethods and compositions for autoimmune and inflammatory diseases treatment // 2639540
FIELD: biotechnology.SUBSTANCE: invention relates to an isolated antibody against RhoB, a fragment thereof, a composition containing it, as well as to a method for suppression of an inflammatory and/or autoimmune disease mediated by B cells and to a method of treatment of a condition or disorder associated with elevated levels of serum immunoglobulin for a subject in need, with its use. An isolated peptide for production of the above antibody is also disclosed, as well as a conjugate and a composition containing it.EFFECT: invention can effectively suppress an inflammatory or autoimmune disease mediated by B cells.19 cl, 10 dwg, 2 ex

Phospho-specific antibodies recognizing tau // 2639537
FIELD: medicine.SUBSTANCE: antibody and its fragment that bind to the phospho-epitope on the Tau protein, as well as the polynucleotides encoding them, are provided; cell lines that produce antibodies; a vector, its host cell and a method for production of the antibody and its functional fragment are proposed. In addition, a pharmaceutical composition, a method for treatment, alleviation or protection against taupathy; a method for induction of a passive immune response in an animal; a method for diagnosis of a protein tau-related disease, disorder or condition, or a predisposition to a protein tau-related disease; a method for monitoring of a minimal residual disease in a patient after treatment with an anti-tau antibody; a method for prediction of patient's response to treatment with an anti-tau antibody; methods for detection of phospho-Tau multimers (pTau) in a brain sample, including postmortem detection; a diagnostic set are proposed.EFFECT: invention can find further application in the diagnosis and therapy of diseases associated with Tau-protein.42 cl, 10 dwg, 15 tbl, 11 ex

Fusion polypeptide containing wap domain and their application methods // 2639526
FIELD: biotechnology.SUBSTANCE: fusion proteins having at least one polypeptide of the human secretory inhibitor of leukocyte proteases (SLPI) operably linked to an immunoglobulin Fc fragment polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:10 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of neutrophilic serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.15 cl, 4 dwg, 4 ex

Pharmaceutical composition for cancer treatment and/or prevention // 2639522
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody that specifically binds to the CAPRIN-1 protein, as well as to a conjugate for treatment or prevention of CAPRIN-1 expressing cancer containing it. A pharmaceutical composition for CAPRIN-1 treatment or prevention, as well as a pharmaceutical combination for CAPRIN-1treatment or prevention containing the above antibody or conjugate is also described. The invention also relates to a method for treatment or prevention of a CAPRIN-1 expression cancer comprising administration of the above antibody, conjugate, composition or combination.EFFECT: invention allows effective treatment or prevention of CAPRIN-1 expressing cancer.12 cl, 8 ex

Antibodies against vascular endothelial growth factor (vegf) // 2639506
FIELD: biotechnology.SUBSTANCE: method is described for blocking or reducing recurrent tumour growth or recurrent growth of cancer cells, comprising administering an effective amount of an anti-VEGF antibody to a subject in need of such treatment, wherein the anti-VEGF antibody comprises: HVR-H1 comprising the amino-acid sequence of SEQ ID NO: 1; HVR-H2 comprising the amino-acid sequence of SEQ ID NO: 2; HVR-H3 comprising the amino-acid sequence of SEQ ID NO: 3; HVR-L1 comprising the amino-acid sequence of SEQ ID NO: 4 or 5; HVR-L2 comprising the amino-acid sequence of SEQ ID NO: 6; and HVR-L3 comprising the amino-acid sequence of SEQ ID NO: 7, or wherein the anti-VEGF antibody comprises a heavy chain variable domain comprising the amino-acid sequence of SEQ ID NO: 43 and a light chain variable domain comprising an amino-acid sequence of SEQ ID NO: 44 or 45. A method of treating a non-neoplastic condition is also described is, comprising administering an effective amount of an anti-VEGF antibody to a subject in need of such treatment, wherein the anti-VEGF antibody is an antibody according to the above method.EFFECT: increased efficiency.19 cl, 16 dwg, 5 ex

Improved high-concentrated liquid preparations of antibodies against tnf-alpha // 2639386
FIELD: pharmacology.SUBSTANCE: group of inventions concerns a liquid aqueous pharmaceutical preparation containing a human anti-TNFα antibody, namely: adalimumab at a concentration of 100 mg/ml, 1 mg/ml of polysorbate-80, 42 mg/ml of mannitol and water. Also, methods for treatment of diseases associated with harmful TNFα activity, by drug administration to the patient are proposed.EFFECT: increased bioavailability with subcutaneous administration to the subject, reduction of pain associated with drug injection in the subject.21 cl, 26 tbl, 9 ex
ethod for anti-tick immunoglobulin production from donor immune plasma // 2639261
FIELD: medicine.SUBSTANCE: preliminary, according to the experimental data of plasma analyzes of a large group of donors, a prognostic calculation of the mean titer of antibodies to the tick-borne encephalitis virus (TBE) of the predicted boiler load (Tav.pred) by the following formula: where T1 is plasma titer of 1:10 IU or less; V1 is the volume of plasma with a titer of 1:10 IU or less; T2 is plasma titer of 1:20 IU; V2 is the volume of plasma titer of 1:20 IU; T3 is plasma titer of 1:40 IU; V3 is the volume of plasma titer of 1:40 IU; T4 is plasma titer of 1:80 IU; V4 is the volume of plasma titer of 1:80 IU; T5 is plasma titer of 1:160 IU; V5 is the volume of plasma titer of 1:160 IU; T6 is plasma titer of 1:320 IU; V6 is the volume of plasma titer of 1:320 IU.EFFECT: increased effectiveness of the use of donor immune plasma to obtain anti-tick immunoglobulin with a titer of antibodies to tick-borne encephalitis virus.2 ex

Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production // 2638457
FIELD: biotechnology.SUBSTANCE: antibodies of the invention specifically bind and block the type 1 receptor of fibroblast growth factor (FGFR1) and are characterized by amino acid sequences of H-CDR1, H-CDR2, H-CDR3, L-CDR1, L-CDR2 and L-CDR3. A pharmaceutical composition for oncological diseases treatment comprising the antibodies of the invention is provided, and a method for oncological diseases treatment, comprising administration of the antibodies of the invention to the patient. A method for antibodies production encoding their nucleic acids and cell lines for antibodies production is also provided.EFFECT: inventions allow to suppress tumour cells proliferation with high efficiency and specificity and inhibit tumour angiogenesis by blocking the pathological pathway, which in turn allows effective treatment of oncological diseases.22 cl, 5 tbl, 5 ex
ethod for directed destruction of cancer cells // 2638446
FIELD: medicine.SUBSTANCE: their preliminary visualization is performed by introduction of a complex consisting of combined photosensitizer molecules, fluorescent nanoparticles fluorescing in the infrared spectral region, and biological recognition molecules into the object under study. The complex further includes one or more plasmon nanoparticles. At that, semiconductor fluorescent nanocrystals that fluoresce in the infrared region of the spectrum are used as fluorescent nanoparticles. Irradiation of cancer cells localization is continued in the optical absorption range of fluorescent nanoparticles for detection of a fluorescent signal from fluorescent nanoparticles and subsequent induction cancer cells destruction process.EFFECT: method provides non-invasive detection and directed destruction of cancer cells localized at great depth, with increased efficiency of visualization and destruction of cancer cells.16 cl, 1 dwg, 1 ex

yocardial infarction treatment using tgf-beta antagonists // 2637088
FIELD: medicine.SUBSTANCE: TGF-β antagonist is introduced, which is an antibody containing the VH-domain of PET1073G12 (SEQ ID NO: 2) and the VL-domain of PET1073G12 (SEQ ID NO: 7). Introduction is carried out within 72 hours from the onset of myocardial ischemia.EFFECT: reduced fibrosis, improved remodeling and myocardial function.20 cl, 2 tbl, 30 dwg, 6 ex

ethods and applications of inhibitors of proprotein convertase subtilisin/kexin, type 9 (pcsk9) // 2636820
FIELD: medicine.SUBSTANCE: proprotein convertase subtilisin/kexin 9 (PCSK9) is administered to a subject in need thereof, wherein the PCSK9 inhibitor is an antibody or an antigen-binding fragment thereof. Also, PCSK9 application is proposed for manufacture of a medicament for sepsis or septic shockr treatment. A pharmaceutical composition and a commercial package containing the PCSK9 inhibitor.EFFECT: possibility of treatment of a patient with sepsis or septic shock at doses suitable for intensive care.21 cl, 5 dwg, 7 tbl

Compositions and methods for treatment and prevention of infections caused by staphylococcus aureus // 2636780
FIELD: pharmacology.SUBSTANCE: composition is described comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising CDR1, CDR2 and CDR3 and a light chain variable domain comprising CDR1, CDR2 and CDR3, wherein the monoclonal antibody specifically binds to protein A (SpA) Staphylococcus aureus with KD less than 1×10-10 M through its Fab site paratope. The monoclonal antibody is able to displace human IgG immunoglobulins associated with SpA on the surface of Staphylococcus aureus bacteria through their Fc regions.EFFECT: significant level of protection against lethal infection with Staphylococcus aureus strain.8 cl, 3 ex

Compositions and methods for diagnosis and treatment of tumour // 2636461
FIELD: biotechnology.SUBSTANCE: variants of antibodies binding tumour-associated antigenic polypeptide TAT425 are proposed. Nucleic acids encoding the antibodies of the invention; a method for determining the presence of TAT425 protein in a sample and a method for diagnosing the presence of a tumour are also contemplated. The invention can find its further application in diagnosing and treating cancer.EFFECT: improved properties of the composition.26 cl, 10 dwg, 1 tbl, 16 ex

odified antibodies composition, methods of production and application // 2636046
FIELD: medicine, pharmacy.SUBSTANCE: group of invention objects refers to the field of biotechnology. An activated antibody is proposed, comprising a) an antibody or antigen binding fragment (AB), binding to the epidermal growth factor receptor (EGFR); b) masking part (MM), which inhibits the specific AB binding with EGFR in the unsplit state, but does not prevent its binding or compete for binding to EGFR in the split state; c) a split part (CM), which acts as a substrate for the protease; and d) linkers (L1 and L2). The activated antibody in the unsplit state has a structure from N-terminus to C-terminus (MM)-L1-(CM)-L2-(AB) and is activated in the target tissue,localized together with the target and protease for CM. A composition for treatment of tumors, autoimmune diseases or inflammatory diseases or for angiogenesis inhibition; application of the activated antibody for medicament preparation; methods for activated antibody preparation and the isolated nucleic acid molecule comprising the nucleotide sequence of the activated antibody are also described.EFFECT: invention provides more efficient delivery of activated antibodies to the target cells and may find further application in medicine.30 cl, 36 dwg, 60 tbl, 19 ex

Anti-vegf/dll4-immunoglobulins with double variable domains and their application // 2636043
FIELD: biotechnology.SUBSTANCE: this protein comprises the first and the second polypeptide chains, each having two variable domains linked by a linker. This invention also relates to compositions comprising this binding protein. The compositions of the invention are intended for treatment of a disease characterized by excessive vascular growth, edema or abnormal expression or activity of DLL4 and/or VEGF. The invention also relates to binding protein application in the manufacture of a drug for treatment of this disease.EFFECT: invention allows preparation of compositions for treatment of a disease characterized by excessive vascular growth, edema or abnormal expression, or DLL4 or VEGF activity.26 cl, 1 dwg, 36 tbl, 15 ex

Compositions for inhibition of masp-2-dependent complement activation // 2636038
FIELD: medicine.SUBSTANCE: isolated human monoclonal antibody and its antigen-binding fragment that bind to human MASP-2 are disclosed. In addition, a nucleic acid molecule encoding the amino acid sequences of the variable regions of the antibody and an antigen-binding fragment are examined; an expression cassette; a cell and a method for production of an isolated anti-MASP-2 antibody or an antigen-binding fragment thereof. A composition for treatment of a condition associated with MASP-2-dependent complement activation; application of an anti-MASP-2 antibody for drug preparation, and an industrial product for treatment of a condition associated with MASP-2-dependent complement activation are also described.EFFECT: can find further application in the therapy of complement-mediated diseases.19 cl, 24 dwg, 30 tbl, 12 ex

Antibodies to pd-l1 and their application for t-cells function strengthening // 2636023
FIELD: biotechnology.SUBSTANCE: isolated antibody to PD-L1 and its antigen-binding fragment, characterized by amino acid sequences of hypervariable regions (HVR) in the heavy chain and light chain variable regions, are proposed. In addition, an isolated nucleic acid encoding the antibody; an expression vector; a host cell and a method for production of an antibody or an antigen-binding fragment thereof are described. Also a composition comprising an effective amount of the antibody to PD-L1 or the antigen-binding fragment; a product of manufacture comprising a container with a therapeutically effective amount of the composition; and methods for malignant tumour and infection treatment are considered.EFFECT: invention can find further application in therapy.60 cl, 11 dwg, 4 tbl, 11 ex
ethod for treatment of macular edema of retina // 2635530
FIELD: medicine.SUBSTANCE: prolonged corticosteroid diprospan is administered to the subtenon space. After 10-15 days, laser coagulation of the retina is performed. After 15-20 days, intravitreal administration of ranibizumab is carried out.EFFECT: improved visual acuity, fast reduction of retinal edema and reduced risk of neovascular complications development.2 ex

ethods of treatment and prevention of stafilococca infections of golden and related disturbances // 2635462
FIELD: medicine.SUBSTANCE: therapeutic compositions of the invention comprise the leukocidin protein and its E and/or D polypeptide and a pharmaceutically acceptable carrier. A method for immunizing a patient against Staphylococcus aureus infection comprises administering a composition for preventing and treating staphylococcus in an amount effective to immunize a patient against Staphylococcus aureus.EFFECT: effective screening, treatment, and prevention of infections of staphylococcus aureus and related disorders.21 cl, 6 dwg, 6 ex, 2 tbl

Stable compositions of antibodies against programmable death receptor of pd-1 person and related treatment // 2633509
FIELD: biotechnology.SUBSTANCE: method of treating a malignant neoplasm in a mammal is described, comprising administering an effective amount of a liquid pharmaceutical composition of an anti-human PD-1 antibody. This method comprises 25-100 mg/ml of anti-human PD-1 antibody; about 70 mg/ml of sucrose; approximately 0.2 mg/ml of polysorbate 80; and approximately 10 mM of histidine buffer at pH of 5.0-6.0, where the human anti-PD-1 antibody comprises: a light chain comprising three CDR sequences of SEQ ID NO: 15.016 and 17; and a heavy chain comprising three CDR sequences of SEQ ID NOs: 18, 19 and 20. In one embodiment, the human anti-PD-1 antibody comprises: a light chain comprising amino acid residues of 20-237 of SEQ ID NO: 36 and a heavy chain comprising amino acid residues of 20-466 of SEQ ID NO: 31.EFFECT: invention extends the arsenal by treating malignant neoplasms in mammals using an anti-human PD-1 antibody.5 cl, 18 dwg, 3 ex, 6 tbl

Pharmaceutical composition for cancer treatment and/or prevention // 2633505
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody for specific binding to a CAPRIN-1 protein, as well as a conjugate, a pharmaceutical composition and a combination drug containing it. The invention also relates to a method for CAPRIN-1 expression cancer treatment or prevention using the above antibody, composition or combination drug.EFFECT: invention effectively treats cancer expressing the CAPRIN-1 protein.15 cl, 8 ex

Proteins binding specific membrane prostate antigen, and related compositions and methods // 2632647
FIELD: biotechnology.SUBSTANCE: invention relates to bispecific binding polypeptide therapeutics specifically targeting cells expressing a specific membrane prostate antigen (SMPA) that can be used in medicine. The resulting polypeptide as well as its dimer and compositions containing them, are used in pharmaceutical compositions for prostate cancer and castration-resistant prostate cancer treatment. The invention allows binding to both SMPA expressing cells and a T-cell receptor complex on T-cells, inducing target-independent T-cell cytotoxicity, activation and proliferation.EFFECT: increased effectiveness of antitumour therapy.26 cl, 8 dwg, 3 tbl, 9 ex

Pharmaceutical composition for cancer treatment and/or prevention // 2632645
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody that specifically binds to an incomplete CAPRIN-1 polypeptide, as well as a pharmaceutical composition, a conjugate and a combined drug containing it. The invention also relates to a method for CAPRIN-1 expression cancer treatment or prevention using the above antibody, composition or combination drug.EFFECT: invention allows effective treatment or prevention of CAPRIN-1 expressing cancer.10 cl, 8 ex

ethod for graft-versus-host reaction identification or treatment // 2632434
FIELD: pharmacology.SUBSTANCE: group of inventions refers to medicine, namely, to transplantology and immunology, and can be used to prepare a pharmaceutical composition for treatment of the graft-versus-host reaction. A pharmaceutical composition for graft-versus-host reaction treatment comprising an anti-CCL8 antibody as an active ingredient. The group of inventions also relates to a method of graft-versus-host reaction treatment comprising anti-CCL8 antibody administration to a subject.EFFECT: use of this group of inventions provides prevention of organ damage in patients with GVHD with the use of CCL8 antibodies.2 cl, 9 ex, 17 dwg

Applications of immunoconjugates, the target of which is cd138 // 2632108
FIELD: medicine.SUBSTANCE: method of treating a disease comprises administering to a human an immunoconjugate comprising at least one engineered targeting antibody targeted by cells expressing CD138 and at least one effector molecule, wherein said engineered targeting antibody is operably linked to said effector molecule to form mentioned immunoconjugate. A portion of the designed targeting antibody imparts IgG4 isotype characteristics, wherein the engineered targeting antibody comprises: (i) a heavy chain having at least 85% sequence identity with SEQ ID NO: 1, wherein the heavy chain comprises a variable region containing amino acid residues 31-35 (CDR1), 51-68 (CDR2) and 99-111 (CDR3) of SEQ ID NO: 1, and (ii) a light chain having at least 85% sequence identity with SEQ ID NO: 2, wherein the light chain comprises a variable A region containing amino acid residues 24-34 (CDR1), 50-56 (CDR2), and 89-97 (CDR3) of the sequence of SEQ ID NO: 2. The effector molecule is a maytansinoid. The immunoconjugate is administered in a cycle of active treatment lasting 21 days, at least three times within the indicated 21 days. The mentioned active treatment cycle comprises the mentioned administration, performed at least once a week, wherein the immunoconjugate is administered at least once a week at a dose of 80 mg/m2 Up to 120 mg/m2. The group of inventions also relates to a kit for treating a disease associated with target cells expressing CD138.EFFECT: use of this group of inventions allows for the introduction of higher doses of immunoconjugate in a multiple-dose regimen with allowance for the limiting toxicity.23 cl, 38 dwg, 24 tbl, 4 ex
Antitumour combinations with mtor inhibitors, herceptin and/or hki-272 // 2632104
FIELD: pharmacology.SUBSTANCE: group of inventions can be used to treat neoplasm associated with excessive expression or amplification of HER2. The use concerns a combination of an mTOR inhibitor selected from the group consisting of rapamycin (sirolimus), 42-O-(2-hydroxy)ethyl rapamycin (etorolimus), CCI-779 (tamsirolimus), and pharmaceutically acceptable salts thereof; And (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide (HKI-272). The method of treatment comprises administering a combination of the mTOR inhibitor and HKI-272. The product of the invention contains an inhibitor of mTOR and HKI-272.EFFECT: use of inventions allows to increase the effectiveness of treatment due to the synergistic effect of the combination.59 cl, 3 tbl, 4 ex

Pharmaceutical composition for cancer treatment or prevention // 2631804
FIELD: pharmacology.SUBSTANCE: antibody or its fragment are described that have immunological reactivity to an incomplete CAPRIN-1 polypeptide consisting of an amino acid sequence specified in SEQ ID NO: 5. A pharmaceutical composition for cancer treatment or prevention comprising the antibody or a fragment thereof as an active ingredient is also described. A method for cancer treatment or prevention, including application of this antibody or a fragment thereof, is also provided. The invention can be applied in a therapeutic or prophylactic agent against cancer.EFFECT: increased efficiency of treatment and prevention.25 cl, 9 ex

Pain treatment // 2630969
FIELD: medicine.SUBSTANCE: granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist is used as an analgesic agent to treat pain. At that, the agent is used to treat pain selected from pain due to bone cancer, pain caused by osteoarthritis, and post-operative pain. The antagonist is a GM-CSF specific antibody comprising the amino acid sequence of the heavy chain variable region of SEQ ID NO: 3 and the amino acid sequence of the light chain variable region of SEQ ID NO: 4.EFFECT: use of the granulocyte-macrophage colony-stimulating factor antagonist is effective for treatment of pain of various genesis.12 ex, 6 dwg

Antibodies for treatment of infection and disease associated with clostridium difficile // 2630663
FIELD: biotechnology.SUBSTANCE: isolated antibodies or their antigen-binding fragments, that specifically bind toxin B and/or A of C. difficile, are described. Also, compositions and kits containing such antibodies are provided. Hybridoma cell lines deposited under access numbers ATCC PTA-9693, ATCC PTA-9692, ATCC PTA-9694, ATCC PTA-9888, where hybridoma produces a monoclonal antibody that specifically binds the toxin of C. difficile, are represented.EFFECT: invention expands arsenal of tools for inhibition or neutralisation of toxicity caused by said toxin.50 cl, 42 dwg, 8 tbl, 13 ex

Humanized antibody to conformational c3 epitope constituent of human complement, dna sequence (versions), expression vector containing dna sequence (versions), and ovarian cells' strain of chinese hamster cho-humc34-producer of this humanized antibody // 2630647
FIELD: biotechnology.SUBSTANCE: invention relates to a humanized antibody, which binds to the C3 epitope of the human complement component. DNA encoding the mentioned antibody, an expression vector, for expressing the mentioned antibody, and also a ovarian cells' strain of chinese hamster which produces the mentioned antibody are also disclosed.EFFECT: invention has the ability to bind specifically to the C3 epitope of the human complement component, which allows the effective treatment of diseases associated with the C3 component of the human complement.12 cl, 6 dwg, 3 ex

Pharmaceutical composition for pancreatic cancer treatment and/or prevention // 2630638
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment or prevention of pancreatic cancer expressing CAPRIN-1, contains an antibody or a fragment thereof in an effective amount that have specific immunological reactivity to the CAPRIN-1 protein, or a conjugate of an antibody or fragment thereof with an antitumor means in an effective amount as an active ingredient, as well as a pharmaceutical combination containing it. A method for treatment or prevention of pancreatic cancer expressing CAPRIN-1, comprising administration of the aforementioned pharmaceutical composition or the aforementioned pharmaceutical combination is also disclosed.EFFECT: invention allows to effectively implement treatment or prevention of pancreatic cancer expressing CAPRIN-1.8 cl, 8 ex

Anti-poly-ubiquitinated antibodies and methods of application // 2630637
FIELD: biotechnology.SUBSTANCE: isolated monoclonal antibody is described, that specifically binds to polyubiquitin containing a C-terminal linkage to the N-terminus, at that, this antibody does not bind specifically to monoubic quinine. A nucleic acid encoding the said antibody, an expression vector comprising the said acid and a host cell are described. An immunoconjugate comprising the said antibody and a cytotoxic agent, as well as a pharmaceutical formulation, are described. Application of the said antibody for the manufacture of a medicament for treatment of a disease or disorder associated with polyubiquitin activity is described. A method is provided for determination of polyubiquitin or polyubiquitinated protein presence in a sample where the polyubiquitin content is assumed, including sample exposure to at least one of the said antibodies and determination of binding of at least one antibody to the polyubiquitin or polyubiquitinated protein in the said sample. A method for polyubiquitinated protein separation is provided.EFFECT: invention provides an antibody that specifically binds to polyubiquitin and does not bind to monoubicquitin.49 cl, 38 dwg, 12 tbl, 5 ex

Improved antibodies gdf-8 antagonists and their use // 2630634
FIELD: biotechnology.SUBSTANCE: antibody or antigen-binding fragment thereof that specifically binds to GDF-8 is described. An antibody or a fragment includes: a variable heavy (VH) antibody region comprising the first, the second and the third complementarity determining regions (CDRs) from the VH region defined by the amino acid sequence of SEQ ID NO: 44; and a variable light (VL) antibody region comprising the first, the second and the third complementarity determining regions (CDRs) from the VL region defined by the amino acid sequence of SEQ ID NO: 46. The aforementioned VH region includes leucine at the amino acid position corresponding to residue number 111 of SEQ ID NO: 44 (position 108 as per Kabat). A pharmaceutical composition containing the described antibody is presented. Also nucleic acids encoding the light and heavy chains of the described antibody are presented.EFFECT: invention allows to obtain improved neutralizing antibodies against GDF-8 capable of being expressed at a much higher level in the host cells than the previously used anti-GDF-8 antibodies, and to expand the arsenal of agents and methods for muscle mass or strength increase and treatment or prevention of muscle disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.65 cl, 12 dwg, 10 tbl, 11 ex
Compositions and methods for beta-glucan immunotherapy // 2629334
FIELD: medicine.SUBSTANCE: composition for enhancement of an immune response to a tumour contains: soluble β-glucan component; an antibody component specifically binding to the soluble β-glucan; and an antitumor antibody. In another aspect, this invention relates to a method to increase the individual response to β-glucan immunotherapy. Application of this invention allows to increase the effectiveness of tumour immunotherapy in an individual, increasing the response to therapy using β-glucan with an antitumor antibody, initiating the cytotoxicity of neutrophils, macrophages and natural killers.EFFECT: increased immune response.30 cl, 11 dwg, 3 ex, 1 tbl
 
2551303.
Up!